Entera Bio Ltd. (ENTX) Q4 2020 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to Interra's BIOS conference call to discuss the financial and operating results for the year end of December 31, 2020. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you'll need to press star 1 on your telephone. If you require any further assistance, please press star then 0. I would now like to turn the call over to John Lieber, the U.S.-based CFO of Interra. Please go ahead. Thank you, and welcome to the call. Joining me on today's call are Spiro Jamas, our CEO, Art Santora, our CMO, and Philip Schwartz, our President of R&D. A press release announcing Interra's financial and operating results for the year-end of December 31, 2020, was issued earlier today. For those of you who have not yet seen it, it is available on the investor section of our website, www.interrabio.com. On our call this morning, we will share with you a business update and review of our financial results, which will be followed by a question and answer session. Before we begin our prepared remarks, I would like to remind you that various statements we make during this call about the company's future results of operations and financial position, our interpretation of interim data from the ongoing Phase II clinical trial of EB613, including the biomarker data released in the first quarter of 2021, the expected timing of data readouts from the ongoing Phase II clinical trial of EB613, Our business strategy and plans and objectives for our future operations are considered forward-looking statements within the meaning of the federal securities laws. Our forward-looking statements are based upon current expectations that involve risks, changes in c...